{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:07:23Z","timestamp":1790050043448,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T00:00:00Z","timestamp":1509148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40256-017-0249-9","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T03:40:15Z","timestamp":1509162015000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Benefit-Risk Assessment of Crataegus Extract WS\u00a01442: An Evidence-Based Review"],"prefix":"10.1007","volume":"18","author":[{"given":"Christian J. F.","family":"Holubarsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson S.","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaan","family":"Eha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,28]]},"reference":[{"key":"249_CR1","volume-title":"Foundation for a new theory and practice of medicine","author":"T Inman","year":"1860","unstructured":"Inman T. Foundation for a new theory and practice of medicine. London: John Churchill; 1860."},{"key":"249_CR2","doi-asserted-by":"publisher","first-page":"f6426","DOI":"10.1136\/bmj.f6426","volume":"347","author":"DK Sokol","year":"2013","unstructured":"Sokol DK. \u201cFirst do no harm\u201d revisited. BMJ. 2013;347:f6426. doi:\n                        10.1136\/bmj.f6426\n                        \n                    .","journal-title":"BMJ"},{"key":"249_CR3","volume-title":"Botanik, Inhaltsstoffe, Qualit\u00e4tskontrolle, Pharmakologie, Toxikologie und Klinik","author":"Kaul R Wei\u00dfdorn Der","year":"1998","unstructured":"Kaul R. Der Wei\u00dfdorn. Botanik, Inhaltsstoffe, Qualit\u00e4tskontrolle, Pharmakologie, Toxikologie und Klinik. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1998."},{"key":"249_CR4","unstructured":"Jennings MC. Crataegus oxyacantha in the treatment of heart disease. N Y Med J. 1896;10(10):491\u20133."},{"key":"249_CR5","unstructured":"Bundesgesundheitsamt. Monographie\u2014Crataegi folium cum flore (Wei\u00dfdornbl\u00e4tter mit Bl\u00fcten). Bundesanzeiger. 1994;133 (19 July 1994):7360\u20131."},{"issue":"1","key":"249_CR6","first-page":"644","volume":"90","author":"American Heart Association","year":"1994","unstructured":"American Heart Association. 1994 Revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation. 1994;90(1):644\u20135.","journal-title":"Circulation"},{"key":"249_CR7","unstructured":"Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Crataegus spp., folium cum flore. London: European Medicines Agency 2016 (5 April 2016). Report No.: EMA\/HMPC\/159075\/2014 Contract No.: EMA\/HMPC\/159075\/2014."},{"key":"249_CR8","unstructured":"Committee on Herbal Medicinal Products (HMPC). Assessment report on Crataegus spp., folium cum flore. London: European Medicines Agency 2016 (5 April 2016). Report No.: EMA\/HMPC\/159076\/2014 Contract No.: EMA\/HMPC\/159076\/2014."},{"issue":"11","key":"249_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1055\/s-0030-1270849","volume":"77","author":"E Koch","year":"2011","unstructured":"Koch E, Malek FA. Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders\u2014preclinical and clinical studies. Planta Med. 2011;77(11):1123\u20138. doi:\n                        10.1055\/s-0030-1270849\n                        \n                    .","journal-title":"Planta Med"},{"key":"249_CR10","doi-asserted-by":"publisher","first-page":"149363","DOI":"10.1155\/2013\/149363","volume":"2013","author":"J Wang","year":"2013","unstructured":"Wang J, Xiong X, Feng B. Effect of Crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid Based Complement Alternat Med. 2013;2013:149363. doi:\n                        10.1155\/2013\/149363\n                        \n                    .","journal-title":"Evid Based Complement Alternat Med."},{"key":"249_CR11","unstructured":"Schmidt-Schweda S, von Burstin J, M\u00f6llmann H, Wollner S, Holubarsch C. Der positiv inotrope Effekt des Crataegus Spezialextrakt WS 1442 in isolierten Myozyten aus menschlichem Vorhof- und Ventrikelmyokrad wird vorwiegend durch oligomere Procyanidine vermittelt. Z Kardiol. 2000;89(Suppl. 5):164, Abstract No. 797."},{"issue":"5","key":"249_CR12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/00005344-200005000-00004","volume":"35","author":"RH Schwinger","year":"2000","unstructured":"Schwinger RH, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol. 2000;35(5):700\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"249_CR13","first-page":"28","volume":"30","author":"K Brixius","year":"1998","unstructured":"Brixius K, Frank K, M\u00fcnch G, M\u00fcller-Ehmsen J, Schwinger RHG. WS 1442 (Crataegus-Spezialextrakt) wirkt am insuffizienten menschlichen Myokard Kontraktionskraft-steigernd. Herz-Kreislauf. 1998;30:28\u201333.","journal-title":"Herz-Kreislauf."},{"key":"249_CR14","unstructured":"M\u00fcnch G, Brixius K, Frank K, Erdmann E. WS 1442 (extract of Crataegus species) increases force of contraction in human failing myocardium by inhibition of the Na+\/K+-ATPase. Circulation. 1997;96(Suppl.):I-729, Abstract No. 4090."},{"key":"249_CR15","first-page":"45","volume":"3","author":"T Krzeminski","year":"1993","unstructured":"Krzeminski T, Chatterjee SS. Ischemia and early reperfusion induced arrythmias: beneficial effects of an extract of Crataegus oxyacantha L. Pharm Pharmacol Lett. 1993;3:45\u20138.","journal-title":"Pharm Pharmacol Lett"},{"key":"249_CR16","unstructured":"Koch E, Chatterjee SS. Crataegus extract WS-1442 enhances coronary flow in the isolated rat heart by endothelial release of nitric oxide. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2000;4(Suppl.):R48 Abstract 180."},{"issue":"3","key":"249_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10557-006-8723-7","volume":"20","author":"K Brixius","year":"2006","unstructured":"Brixius K, Willms S, Napp A, et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther. 2006;20(3):177\u201384.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"249_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/FJC.0b013e31819ccfc9","volume":"53","author":"E Anselm","year":"2009","unstructured":"Anselm E, Socorro VF, Dal-Ros S, Schott C, Bronner C, Schini-Kerth VB. Crataegus special extract WS 1442 causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of endothelial NO synthase but not via activation of estrogen receptors. J Cardiovasc Pharmacol. 2009;53(3):253\u201360. doi:\n                        10.1097\/FJC.0b013e31819ccfc9\n                        \n                    .","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"249_CR19","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/gerona\/glv213","volume":"71","author":"S Khemais-Benkhiat","year":"2015","unstructured":"Khemais-Benkhiat S, Idris-Khodja N, Ribeiro TP, et al. The redox-sensitive induction of the local angiotensin system promotes both premature and replicative endothelial senescence: preventive effect of a standardized Crataegus extract. J Gerontol A Biol Sci Med Sci. 2016;71(12):1581\u201390.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8\u20139","key":"249_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.phymed.2012.04.005","volume":"19","author":"N Idris-Khodja","year":"2012","unstructured":"Idris-Khodja N, Auger C, Koch E, Schini-Kerth VB. Crataegus special extract WS\u00ae 1442 prevents aging-related endothelial dysfunction. Phytomedicine. 2012;19(8\u20139):699\u2013706. doi:\n                        10.1016\/j.phymed.2012.04.005\n                        \n                    .","journal-title":"Phytomedicine"},{"issue":"1","key":"249_CR21","doi-asserted-by":"publisher","first-page":"e29972","DOI":"10.1371\/journal.pone.0029972","volume":"7","author":"W Peters","year":"2012","unstructured":"Peters W, Druppel V, Kusche-Vihrog K, Schubert C, Oberleithner H. Nanomechanics and sodium permeability of endothelial surface layer modulated by hawthorn extract WS 1442. PLoS One. 2012;7(1):e29972. doi:\n                        10.1371\/journal.pone.0029972\n                        \n                    .","journal-title":"PLoS One"},{"issue":"1","key":"249_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.phymed.2011.08.059","volume":"19","author":"E Rieckeheer","year":"2011","unstructured":"Rieckeheer E, Schwinger RH, Bloch W, Brixius K. Hawthorn special extract WS\u00ae 1442 increases red blood cell NO-formation without altering red blood cell deformability. Phytomedicine. 2011;19(1):20\u20134. doi:\n                        10.1016\/j.phymed.2011.08.059\n                        \n                    .","journal-title":"Phytomedicine"},{"issue":"6","key":"249_CR23","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00424-014-1577-0","volume":"467","author":"H Oberleithner","year":"2015","unstructured":"Oberleithner H. Sodium selective erythrocyte glycocalyx and salt sensitivity in man. Pflugers Arch. 2015;467(6):1319\u201325. doi:\n                        10.1007\/s00424-014-1577-0\n                        \n                    .","journal-title":"Pflugers Arch"},{"issue":"5","key":"249_CR24","first-page":"783","volume":"24","author":"WH M\u00e4vers","year":"1974","unstructured":"M\u00e4vers WH, Hensel H. Ver\u00e4nderungen der lokalen Myokarddurchblutung nach oraler Gabe eines Crataegusextraktes bei nichtnarkotisierten Hunden. Arzneimittelforschung. 1974;24(5):783\u20135.","journal-title":"Arzneimittelforschung"},{"key":"249_CR25","doi-asserted-by":"publisher","unstructured":"Ribeiro TP, Auger C, Jabeen Q, et al. Intake of a standardized Crataegus extract prevents DOCA-salt-induced hypertension, and alteration of cardiac, vascular and renal structure and function in rats: Role of oxidative stress. Clin Res Cardiol. 2015;104(Suppl. 1):Abstract P1828. doi:\n                        10.1007\/s00392-015-1100-4\n                        \n                    .","DOI":"10.1007\/s00392-015-1100-4"},{"key":"249_CR26","unstructured":"Kurcok A. Ischemia- and perfusion-induced cardiac injury: effects of two flavonoid containing plant extracts possessing radical scavenging properties. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 1992;345(Suppl.):R81 Abstract 322."},{"issue":"15","key":"249_CR27","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.lfs.2003.09.050","volume":"74","author":"M Veveris","year":"2004","unstructured":"Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci. 2004;74(15):1945\u201355. doi:\n                        10.1016\/j.lfs.2003.09.050\n                        \n                    .","journal-title":"Life Sci"},{"issue":"7","key":"249_CR28","first-page":"821","volume":"47","author":"SS Chatterjee","year":"1997","unstructured":"Chatterjee SS, Koch E, Jaggy H, Krzeminski T. In-vitro- und In-vivo-Untersuchungen zur kardioprotektiven Wirkung von oligomeren Procyanidinen in einem Crataegus-Extrakt aus Bl\u00e4ttern mit Bl\u00fcten. Arzneimittelforschung. 1997;47(7):821\u20135.","journal-title":"Arzneimittelforschung"},{"key":"249_CR29","doi-asserted-by":"publisher","unstructured":"Koch E, Sp\u00f6rl-Aich G. Oral treatment with the Crataegus special extract WS\u00ae 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension. Planta Med. 2006;72(11):P_265. doi:\n                        10.1055\/s-2006-950065\n                        \n                    .","DOI":"10.1055\/s-2006-950065"},{"issue":"1","key":"249_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10557-008-6082-2","volume":"22","author":"HS Hwang","year":"2008","unstructured":"Hwang HS, Bleske BE, Ghannam MM, et al. Effects of hawthorn on cardiac remodeling and left ventricular dysfunction after 1\u00a0month of pressure overload-induced cardiac hypertrophy in rats. Cardiovasc Drugs Ther. 2008;22(1):19\u201328. doi:\n                        10.1007\/s10557-008-6082-2\n                        \n                    .","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"249_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1592\/phco.29.6.639","volume":"29","author":"HS Hwang","year":"2009","unstructured":"Hwang HS, Boluyt MO, Converso K, Russell MW, Bleske BE. Effects of hawthorn on the progression of heart failure in a rat model of aortic constriction. Pharmacotherapy. 2009;29(6):639\u201348. doi:\n                        10.1592\/phco.29.6.639\n                        \n                    .","journal-title":"Pharmacotherapy."},{"key":"249_CR32","unstructured":"Koch E, Chatterjee SS. Crataegus extract WS-1442 compensates the decrease of cardiac output in endotoxemic rats. In: 3rd symposium on cytokines and apoptosis in the cardiovascular system; 27\u201328 Jan 2000; Halle. 2000."},{"issue":"1","key":"249_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pauz.200400104","volume":"34","author":"K Brixius","year":"2005","unstructured":"Brixius K, Willms S, Schwinger RH. Grundlage f\u00fcr die Therapie kardiovaskul\u00e4rer Erkrankungen: Zellul\u00e4re und molekulare Wirkmechanismen von Crataegus-Extrakt. Pharm Unserer Zeit. 2005;34(1):48\u201351. doi:\n                        10.1002\/pauz.200400104\n                        \n                    .","journal-title":"Pharm Unserer Zeit"},{"key":"249_CR34","doi-asserted-by":"publisher","unstructured":"Koch E, Lanzend\u00f6rfer-Goossens H, Weibezahn C. Crataegus-Spezialextrakt WS\u00ae 1442 hemmt die Sekretion von Apolipoprotein B100 (ApoB) und erh\u00f6ht die Transkription des Low-Density Lipoproteinrezeptors (LDL-R) in humanen HepG2-Zellen. Z Phytother. 2006;27(S 1):P17. doi:\n                        10.1055\/s-2006-954919\n                        \n                    .","DOI":"10.1055\/s-2006-954919"},{"key":"249_CR35","volume-title":"Untersuchung zur Biogenese, Markierung und Pharkakokinetik der Procyanidine aus Crataegus-Species","author":"AE Hecker-Niediek","year":"1983","unstructured":"Hecker-Niediek AE. Untersuchung zur Biogenese, Markierung und Pharkakokinetik der Procyanidine aus Crataegus-Species. Marburg: Philipps-Universit\u00e4t; 1983."},{"issue":"6","key":"249_CR36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00002018-200629060-00005","volume":"29","author":"C Daniele","year":"2006","unstructured":"Daniele C, Mazzanti G, Pittler MH, Ernst E. Adverse-event profile of Crataegus spp.: a systematic review. Drug Saf. 2006;29(6):523\u201335.","journal-title":"Drug Saf"},{"issue":"5","key":"249_CR37","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1067\/mhj.2002.121463","volume":"143","author":"M Tauchert","year":"2002","unstructured":"Tauchert M. Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J. 2002;143(5):910\u20135.","journal-title":"Am Heart J"},{"key":"249_CR38","doi-asserted-by":"crossref","unstructured":"Tauchert M, Gildor A, Lipinski J. Einsatz des hochdosierten Crataegusextraktes WS 1442 in der Therapie der Herzinsuffizienz Stadium NYHA II. Herz. 1999;24(6):465\u201374.","DOI":"10.1007\/BF03044432"},{"issue":"4","key":"249_CR39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1388-9842(00)00109-4","volume":"2","author":"CJ Holubarsch","year":"2000","unstructured":"Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE)\u2014rationale, study design and study protocol. Eur J Heart Fail. 2000;2(4):431\u20137.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"249_CR40","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ejheart.2008.10.004","volume":"10","author":"CJ Holubarsch","year":"2008","unstructured":"Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail. 2008;10(12):1255\u201363. doi:\n                        10.1016\/j.ejheart.2008.10.004\n                        \n                    .","journal-title":"Eur J Heart Fail"},{"issue":"10 Suppl","key":"249_CR41","doi-asserted-by":"crossref","first-page":"N158","DOI":"10.1097\/00003246-200010001-00008","volume":"28","author":"GM Chaudhry","year":"2000","unstructured":"Chaudhry GM, Haffajee CI. Antiarrhythmic agents and proarrhythmia. Crit Care Med. 2000;28(10 Suppl):N158\u201364.","journal-title":"Crit Care Med"},{"issue":"4","key":"249_CR42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11886-999-0052-6","volume":"1","author":"PJ Podrid","year":"1999","unstructured":"Podrid PJ. Proarrhythmia, a serious complication of antiarrhythmic drugs. Curr Cardiol Rep. 1999;1(4):289\u201396.","journal-title":"Curr Cardiol Rep."},{"issue":"10","key":"249_CR43","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/eurjhf\/hfp116","volume":"11","author":"SM Zick","year":"2009","unstructured":"Zick SM, Vautaw BM, Gillespie B, Aaronson KD. Hawthorn extract randomized blinded chronic heart failure (HERB CHF) trial. Eur J Heart Fail. 2009;11(10):990\u20139. doi:\n                        10.1093\/eurjhf\/hfp116\n                        \n                    .","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"249_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejheart.2008.04.008","volume":"10","author":"SM Zick","year":"2008","unstructured":"Zick SM, Gillespie B, Aaronson KD. The effect of Crataegus oxycantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail. 2008;10(6):587\u201393. doi:\n                        10.1016\/j.ejheart.2008.04.008\n                        \n                    .","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"249_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/sports2030059","volume":"2","author":"S H\u00e4rtel","year":"2014","unstructured":"H\u00e4rtel S, Kutzner C, Westphal E, et al. Effects of endurance exercise training and Crataegus extract WS\u00ae 1442 in patients with heart failure with preserved ejection fraction\u2014a randomized controlled trial. Sports. 2014;2(3):59\u201375. doi:\n                        10.3390\/sports2030059\n                        \n                    .","journal-title":"Sports."},{"key":"249_CR46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1201\/b14669-51","volume-title":"Encyclopedia of dietary supplements","author":"E Koch","year":"2010","unstructured":"Koch E, Busse WR, Juretzek W, Chevts V. Hawthorn. In: Coates PM, Betz JM, Blackman MR, Cragg GM, Levine M, Moss J, et al., editors. Encyclopedia of dietary supplements. 2nd ed. New York: Informa Healthcare; 2010. p. 411\u201322.","edition":"2"},{"issue":"6","key":"249_CR47","first-page":"637","volume":"43","author":"R Tankanow","year":"2003","unstructured":"Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol. 2003;43(6):637\u201342.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"249_CR48","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(10):933\u201389. doi:\n                        10.1016\/j.ejheart.2008.08.005\n                        \n                    .","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"249_CR49","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803\u201369. doi:\n                        10.1093\/eurjhf\/hfs105\n                        \n                    .","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"249_CR50","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ejheart.2005.07.003","volume":"7","author":"I Ekman","year":"2005","unstructured":"Ekman I, Cleland JG, Andersson B, Swedberg K. Exploring symptoms in chronic heart failure. Eur J Heart Fail. 2005;7(5):699\u2013703. doi:\n                        10.1016\/j.ejheart.2005.07.003\n                        \n                    .","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"249_CR51","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810\u201352. doi:\n                        10.1161\/CIR.0b013e31829e8807\n                        \n                    .","journal-title":"Circulation"},{"key":"249_CR52","doi-asserted-by":"publisher","unstructured":"Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev. 2008(1):CD005312. doi:\n                        10.1002\/14651858.CD005312.pub2\n                        \n                    .","DOI":"10.1002\/14651858.CD005312.pub2"},{"key":"249_CR53","unstructured":"B\u00f6digheimer K, Chase D. Wirksamkeit von Wei\u00dfdorn-Extrakt in der Dosierung 3 mal 100\u00a0mg t\u00e4glich. Multizentrische Doppelblindstudie mit 85 herzinsuffizienten Patienten im Stadium NYHA II. M\u00fcnch Med Wschr. 1994;136(Suppl. 1):S7\u201311."},{"key":"249_CR54","first-page":"4331","volume":"33","author":"T Hanak","year":"1983","unstructured":"Hanak T, Br\u00fcckel MH. Behandlung von leichten stabilen Formen der Angina pectoris mit Crataegutt\u00ae novo. Therapiewoche. 1983;33:4331\u20133.","journal-title":"Therapiewoche."},{"key":"249_CR55","doi-asserted-by":"crossref","unstructured":"Zapfe jun G. Clinical efficacy of Crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine. 2001;8(4):262\u20136.","DOI":"10.1078\/0944-7113-00041"},{"key":"249_CR56","first-page":"352","volume":"111","author":"H Leuchtgens","year":"1993","unstructured":"Leuchtgens H, Crataegus-Spezialextrakt WS. 1442 bei Herzinsuffizienz NYHA II. Fortschr Med. 1993;111:352\u20134.","journal-title":"Fortschr Med"},{"issue":"24","key":"249_CR57","first-page":"291","volume":"114","author":"A Weikl","year":"1996","unstructured":"Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus-Spezialextrakt WS 1442. Objektiver Wirksamkeitsnachweis bei Patienten mit Herzinsuffizienz (NYHA II). Fortschr Med. 1996;114(24):291\u20136.","journal-title":"Fortschr Med"},{"key":"249_CR58","unstructured":"O\u2019Connolly M, Bernh\u00f6ft G, Bartsch G. Behandlung \u00e4lterer, multimorbider Patienten mit stenokardischen Beschwerden. Eine placebokontrollierte Cross-over-Doppelblindstudie mit Crataegutt\u00ae novo. Therapiewoche. 1987;37:3587\u2013600."},{"issue":"42","key":"249_CR59","first-page":"805","volume":"104","author":"M O\u2019Connolly","year":"1986","unstructured":"O\u2019Connolly M, Jansen W, Bernh\u00f6ft G, Bartsch G. Behandlung der nachlassenden Herzleistung. Therapie mit standardisiertem Crataegus-Extrakt im hoheren Lebensalter. Fortschr Med. 1986;104(42):805\u20138.","journal-title":"Fortschr Med"},{"key":"249_CR60","first-page":"212","volume":"14","author":"H Eichst\u00e4dt","year":"2001","unstructured":"Eichst\u00e4dt H, St\u00f6rk T, M\u00f6ckel M, Danne O, Funk P, K\u00f6hler S. Wirksamkeit und Vertr\u00e4glichkeit von Crataegus-Extrakt WS 1442 bei herzinsuffizienten Patienten mit eingeschr\u00e4nkter linksventrikul\u00e4rer Funktion. Perfusion. 2001;14:212\u20137.","journal-title":"Perfusion."},{"key":"249_CR61","first-page":"1908","volume":"21","author":"D Zerssen von","year":"1971","unstructured":"von Zerssen D. Die Beschwerden-Liste als Test. Therapiewoche. 1971;21:1908\u201320.","journal-title":"Die Beschwerden-Liste als Test. Therapiewoche."},{"key":"249_CR62","unstructured":"Siegrist J, Junge A. Lebensqualit\u00e4t unter antihypertensiver Therapie. Herz. 1987;12(Suppl. I):10\u20135."},{"issue":"3","key":"249_CR63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"5","key":"249_CR64","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"249_CR65","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","volume":"8","author":"AL Bui","year":"2011","unstructured":"Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30\u201341. doi:\n                        10.1038\/nrcardio.2010.165\n                        \n                    .","journal-title":"Nat Rev Cardiol."},{"issue":"5","key":"249_CR66","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0735-6757(96)90147-3","volume":"14","author":"RM Goldberg","year":"1996","unstructured":"Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447\u201350. doi:\n                        10.1016\/S0735-6757(96)90147-3\n                        \n                    .","journal-title":"Am J Emerg Med"},{"issue":"3","key":"249_CR67","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000368191","volume":"61","author":"PS Nishtala","year":"2015","unstructured":"Nishtala PS, Salahudeen MS. Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005\u20132013. Gerontology. 2015;61(3):195\u2013202. doi:\n                        10.1159\/000368191\n                        \n                    .","journal-title":"Gerontology."},{"issue":"4","key":"249_CR68","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000365328","volume":"61","author":"C G\u00f3mez","year":"2015","unstructured":"G\u00f3mez C, Vega-Quiroga S, Bermejo-Pareja F, Medrano MJ, Louis ED, Benito-Le\u00f3n J. Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). Gerontology. 2015;61(4):301\u20139. doi:\n                        10.1159\/000365328\n                        \n                    .","journal-title":"Gerontology."},{"issue":"1","key":"249_CR69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","volume":"13","author":"RL Maher Jr","year":"2014","unstructured":"Maher RL Jr, Hanlon JT, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57\u201365. doi:\n                        10.1517\/14740338.2013.827660\n                        \n                    .","journal-title":"Expert Opin Drug Saf."},{"issue":"6","key":"249_CR70","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1024\/0040-5930\/a000524","volume":"71","author":"B Wickop","year":"2014","unstructured":"Wickop B, Langebrake C. Gute Verordnungspraxis bei \u00e4lteren Patienten. Ther Umsch. 2014;71(6):366\u201373. doi:\n                        10.1024\/0040-5930\/a000524\n                        \n                    .","journal-title":"Ther Umsch"},{"issue":"1","key":"249_CR71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0735-1097(93)90816-J","volume":"22","author":"M Packer","year":"1993","unstructured":"Packer M, Narahara KA, Elkayam U, et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. J Am Coll Cardiol. 1993;22(1):65\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"249_CR72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.29333\/ejgm\/82363","volume":"10","author":"AH Alhusseiny","year":"2013","unstructured":"Alhusseiny AH, Al-Nimer MSM, Latif II, Ibrahim AK. Heart failure: discrepancy between NYHA functional classification, serum NT-pro brain natriuretic peptide and ejection fraction. Eur J Gen Med. 2013;10(1):26\u201331.","journal-title":"Eur J Gen Med."},{"issue":"9386","key":"249_CR73","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777\u201381. doi:\n                        10.1016\/S0140-6736(03)14285-7\n                        \n                    .","journal-title":"Lancet"},{"issue":"19","key":"249_CR74","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338\u201345. doi:\n                        10.1093\/eurheartj\/ehl250\n                        \n                    .","journal-title":"Eur Heart J"},{"key":"249_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.876","author":"M Komajda","year":"2017","unstructured":"Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;. doi:\n                        10.1002\/ejhf.876\n                        \n                    .","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"249_CR76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2012.12.002","volume":"1","author":"LS Maier","year":"2013","unstructured":"Maier LS, Layug B, Karwatowska-Prokopczuk E, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013;1(2):115\u201322. doi:\n                        10.1016\/j.jchf.2012.12.002\n                        \n                    .","journal-title":"JACC Heart Fail."},{"issue":"5","key":"249_CR77","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","volume":"114","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397\u2013403. doi:\n                        10.1161\/CIRCULATIONAHA.106.628347\n                        \n                    .","journal-title":"Circulation"},{"issue":"8","key":"249_CR78","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781\u201391. doi:\n                        10.1001\/jama.2013.905\n                        \n                    .","journal-title":"JAMA"},{"issue":"23","key":"249_CR79","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456\u201367. doi:\n                        10.1056\/NEJMoa0805450\n                        \n                    .","journal-title":"N Engl J Med"},{"issue":"15","key":"249_CR80","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392. doi:\n                        10.1056\/NEJMoa1313731\n                        \n                    .","journal-title":"N Engl J Med"},{"key":"249_CR81","doi-asserted-by":"publisher","first-page":"P15","DOI":"10.1055\/s-0032-1313255","volume":"33","author":"S H\u00e4rtel","year":"2012","unstructured":"H\u00e4rtel S, Kutzner C, Burkart M, B\u00f6s K. Einfluss von Training und Crataegus-Extrakt WS\u00ae 1442 auf k\u00f6rperliche Leistungsf\u00e4higkeit und Lebensqualit\u00e4t bei leichter Herzinsuffizienz\u2014eine randomisierte kontrollierte Studie. Z Phytother. 2012;33:P15. doi:\n                        10.1055\/s-0032-1313255\n                        \n                    .","journal-title":"Z Phytother."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-017-0249-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0249-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0249-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T11:51:48Z","timestamp":1516189908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-017-0249-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,28]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1007\/s40256-017-0249-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,28]]}}}